Physician profile
Niloo Prasad
NPI 1407862519
$7,969.54
in general payments reported to CMS, 2019-2025
57 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $863 · 2021: $655 · 2022: $1,454 · 2023: $1,389 · 2024: $1,260 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659 · Education: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.94 |
| Education | $527.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,043.16 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $987.48 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $696.77 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Daiichi Sankyo INC. | $378.62 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $348.56 | 2019-2025 | |
| Astellas Pharma US INC | $347.17 | 2020-2024 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $338.83 | 2019-2025 | |
| Eisai INC. | $316.26 | 2023-2025 | |
| Gilead Sciences, INC. | $314.78 | 2022-2025 | Trodelvy |
| Celgene Corporation | $271.95 | 2019-2023 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $261.88 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Seagen INC. | $220.81 | 2020-2024 | Padcev |
| Merck Sharp & Dohme LLC | $183.56 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $160.41 | 2022-2025 | Fotivda |
| Lilly USA, LLC | $152.13 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niloo Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.